user

Prospective Randomized Trial of Sirolimus (SRL) and Mycophenolate Mofetil (MMF) vs. Tacrolimus (TAC) plus MMF Therapy Following Thymoglobulin (THY) Induction with Rapid Steroid Taper (RST) in Primary Kidney Transplantation (KTX).

被引：0
|
作者：
Gonwa, Thomas A. [1 ]
Heilman, Raymond L. [2 ]
Wadei, Hani M. [1 ]
Reddy, Kunam S. [2 ]
Mai, Martin L. [1 ]
Mazur, Marek [2 ]
Ahsan, Nasimul [1 ]
Younan, Kerri [1 ]
Mulligan, David C. [2 ]
Grewal, Hani [1 ]
机构：
[1] Mayo Clin, Jacksonville, FL USA
[2] Mayo Clin, Scottsdale, AZ USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2009年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
下载
收藏
页码：341 / 341
页数：1
相关论文
共 30 条
  • [21] Thymoglobulin Plus Basiliximab vs Basiliximab as Induction Therapy in Deceased Donor Kidney Transplant Recipients Treated with Tacrolimus and Mycophenolate Mofetil: 1-Year Results of a Prospective Clinical Trial.
    Favi, E.
    Spagnoletti, G.
    Silvestrini, N.
    Salerno, M.
    Pedroso, J.
    Romagnoli, J.
    Citterio, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 426 - 426
  • [22] Final 36 Month Results of a Randomized Trial Comparing Three Induction Agents (Alemtuzumab, Thymoglobulin and Basiliximab) with Tacrolimus, Mycophenolate Mofetil and Rapid Steroid Withdrawal in Renal Transplantation.
    Peddi, Ram
    Hanaway, Michael
    Woodle, Steve
    Mulgaonkar, Shamkant
    Harrison, Gilda
    Vandeputte, Karen
    Fitzsimmons, William
    First, Roy
    Holman, John
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 49 - 49
  • [23] 12 month results of a multicenter, randomized trial comparing three induction agents (alemtuzumab, thymoglobulin and basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation.
    Hanaway, Michael
    Woodle, E. Steve
    Mulgaonkar, Shamkant
    Peddi, Ram
    Harrison, Gilda
    Vandeputte, Karen
    Fitzsimmons, William
    First, Roy
    Holman, John
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 215 - 215
  • [24] A randomized, open-label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with tacrolimus (TAC) plus mycophenolate mofetil (MMF) in De Novo renal allograft recipients:: Preliminary 2-year safety results from the ORION trial
    Flechner, Stuart M.
    Cockfield, Sandra
    Grinyo, Josep
    Russ, Graeme
    Wissing, K. Martin
    Legendre, Christophe
    Copley, J. Brian
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 582 - 582
  • [25] A randomized, open-label study to compare the efficacy and safety of two different sirolimus (SRL) regimens with tacrolimus (TAC) plus mycophenolate mofetil (MMF) in de novo renal allograft recipients: Preliminary 2-year efficacy results from the ORION trial
    Flechner, Stuart M.
    Cockfield, Sandra
    Grinyo, Josep
    Russ, Graeme
    Wissing, K. Martin
    Legendre, Christophe
    Copley, J. Brian
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 254 - 254
  • [26] CHARACTERIZING STEROID-FREE REGIMENS POST LIVER TRANSPLANTATION: RANDOMIZED PHASE III TRIAL COMPARING TACROLIMUS MONOTHERAPY AFTER DACLIZUMAB INDUCTION AND TACROLIMUS plus MMF DUAL THERAPY
    Cillo, U.
    Otto, G.
    Becker, T.
    LIVER TRANSPLANTATION, 2009, 15 (07) : S96 - S96
  • [27] ER-TACROLIMUS PLUS EVEROLIMUS VS ER-TACROLIMUS PLUS MMF IN PRIMARY DECEASED DONOR KIDNEY TRANSPLANTATION: 1-YEAR RESULTS OF SINGLE CENTER, OPEN LABEL, PROSPECTIVE, RANDOMIZED CLINICAL TRIAL
    Favi, Evaldo
    Silvestrini, Nicola
    Pedroso, Jose Alberto
    Salerno, Maria Paola
    Spagnoletti, Gionata
    Romagnoli, Jacopo
    Citterio, Franco
    TRANSPLANT INTERNATIONAL, 2013, 26 : 241 - 241
  • [28] Continuing 24 Month Results of a Multicenter, Randomized Trial Comparing Three Induction Agents (Alemtuzumab, Thymoglobulin and Basiliximab) with Tacrolimus, Mycophenolate Mofetil and a Rapid Steroid Withdrawal in Renal Transplantation.
    Mulgaonkar, Shamkant
    Hanaway, Michael
    Woodle, E. Steve
    Peddi, Ram
    Harrison, Gilda
    Vandeputte, Karen
    Fitzsimmons, William
    First, Roy
    Holman, John
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 282 - 282
  • [29] Impact on Renal Function of Early Conversion at 3 Months from Cyclosporine (CsA) to Sirolimus (SRL) in Association with Mycophenolate Mofetil (MMF) in Kidney Transplantation: 30-Months Follow up of a Multicenter Randomized Controlled Trial: The Concept Study.
    Lebranchu, Y.
    Toupance, O.
    Touchard, G.
    Thervet, E.
    Etienne, I.
    Mazouz, H.
    de Ligny, B. Hurault
    Moulin, B.
    Rerolle, J. P.
    Frouget, T.
    Glotz, D.
    Randoux, C.
    Bayle, F.
    Heng, A. E.
    Allano, F.
    Buchler, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 260 - 260
  • [30] 1-Year Outcomes of a Prospective, Open Label, Randomized, Controlled Trial of Standard vs Extended-Release Tacrolimus as Maintenance Monotherapy in Kidney Transplantation after Alemtuzumab Induction with Rapid Steroid Withdrawal (TAESR Trial).
    McLean, A.
    Chan, K.
    Galliford, J.
    Goodall, D.
    Charif, R.
    Willicombe, M.
    Roufosse, C.
    Cook, T.
    Taube, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 358 - 358
123